93 related articles for article (PubMed ID: 6184384)
1. Inactivation of kallikrein in human plasma.
van der Graaf F; Koedam JA; Bouma BN
J Clin Invest; 1983 Jan; 71(1):149-58. PubMed ID: 6184384
[TBL] [Abstract][Full Text] [Related]
2. The plasma kallikrein-kinin system and risk of cardiovascular disease in men.
Govers-Riemslag JW; Smid M; Cooper JA; Bauer KA; Rosenberg RD; Hack CE; Hamulyak K; Spronk HM; Miller GJ; ten Cate H
J Thromb Haemost; 2007 Sep; 5(9):1896-903. PubMed ID: 17723129
[TBL] [Abstract][Full Text] [Related]
3. Protease inhibitor plasma concentrations associate with COVID-19 infection.
Medjeral-Thomas NR; Troldborg A; Hansen AG; Pihl R; Clarke CL; Peters JE; Thomas DC; Willicombe M; Palarasah Y; Botto M; Pickering MC; Thiel S
Oxf Open Immunol; 2021; 2(1):iqab014. PubMed ID: 34458849
[TBL] [Abstract][Full Text] [Related]
4. Human plasma kallikrein: roles in coagulation, fibrinolysis, inflammation pathways, and beyond.
Motta G; Juliano L; Chagas JR
Front Physiol; 2023; 14():1188816. PubMed ID: 37711466
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulant SERPINs: Endogenous Regulators of Hemostasis and Thrombosis.
Grover SP; Mackman N
Front Cardiovasc Med; 2022; 9():878199. PubMed ID: 35592395
[TBL] [Abstract][Full Text] [Related]
6. Heat-Inactivation of Human Serum Destroys C1 Inhibitor, Pro-motes Immune Complex Formation, and Improves Human T Cell Function.
Fante MA; Decking SM; Bruss C; Schreml S; Siska PJ; Kreutz M; Renner K
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33808005
[TBL] [Abstract][Full Text] [Related]
7. Proteolytic activity of contact factor zymogens.
Shamanaev A; Emsley J; Gailani D
J Thromb Haemost; 2021 Feb; 19(2):330-341. PubMed ID: 33107140
[TBL] [Abstract][Full Text] [Related]
8. Prekallikrein inhibits innate immune signaling in the lung and impairs host defense during pneumosepsis in mice.
Ding C; Scicluna BP; Stroo I; Yang J; Roelofs JJ; de Boer OJ; de Vos AF; Nürnberg P; Revenko AS; Crosby J; Van't Veer C; van der Poll T
J Pathol; 2020 Jan; 250(1):95-106. PubMed ID: 31595971
[TBL] [Abstract][Full Text] [Related]
9. Innate networking: Thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient.
Manook M; Kwun J; Sacks S; Dorling A; Mamode N; Knechtle S
Transplant Rev (Orlando); 2018 Jul; 32(3):119-126. PubMed ID: 29935708
[TBL] [Abstract][Full Text] [Related]
10. Negatively charged silver nanoparticles cause retinal vascular permeability by activating plasma contact system and disrupting adherens junction.
Long YM; Zhao XC; Clermont AC; Zhou QF; Liu Q; Feener EP; Yan B; Jiang GB
Nanotoxicology; 2016; 10(4):501-11. PubMed ID: 26399585
[TBL] [Abstract][Full Text] [Related]
11. Cysteine proteinase from Streptococcus pyogenes enables evasion of innate immunity via degradation of complement factors.
Honda-Ogawa M; Ogawa T; Terao Y; Sumitomo T; Nakata M; Ikebe K; Maeda Y; Kawabata S
J Biol Chem; 2013 May; 288(22):15854-64. PubMed ID: 23589297
[TBL] [Abstract][Full Text] [Related]
12. Systems biology of coagulation initiation: kinetics of thrombin generation in resting and activated human blood.
Chatterjee MS; Denney WS; Jing H; Diamond SL
PLoS Comput Biol; 2010 Sep; 6(9):. PubMed ID: 20941387
[TBL] [Abstract][Full Text] [Related]
13. Chemically oversulfated glycosaminoglycans are potent modulators of contact system activation and different cell signaling pathways.
Pan J; Qian Y; Zhou X; Lu H; Ramacciotti E; Zhang L
J Biol Chem; 2010 Jul; 285(30):22966-75. PubMed ID: 20418371
[TBL] [Abstract][Full Text] [Related]
14. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation.
Maas C; Govers-Riemslag JW; Bouma B; Schiks B; Hazenberg BP; Lokhorst HM; Hammarström P; ten Cate H; de Groot PG; Bouma BN; Gebbink MF
J Clin Invest; 2008 Sep; 118(9):3208-18. PubMed ID: 18725990
[TBL] [Abstract][Full Text] [Related]
15. Biological activities of C1 inhibitor.
Davis AE; Mejia P; Lu F
Mol Immunol; 2008 Oct; 45(16):4057-63. PubMed ID: 18674818
[TBL] [Abstract][Full Text] [Related]
16. New treatments addressing the pathophysiology of hereditary angioedema.
Davis AE
Clin Mol Allergy; 2008 Apr; 6():2. PubMed ID: 18410689
[TBL] [Abstract][Full Text] [Related]
17. C1 inhibitor: molecular and clinical aspects.
Cicardi M; Zingale L; Zanichelli A; Pappalardo E; Cicardi B
Springer Semin Immunopathol; 2005 Nov; 27(3):286-98. PubMed ID: 16267649
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of C1 esterase inhibitor by StcE, a metalloprotease secreted by Escherichia coli O157:H7.
Lathem WW; Bergsbaken T; Welch RA
J Exp Med; 2004 Apr; 199(8):1077-87. PubMed ID: 15096536
[TBL] [Abstract][Full Text] [Related]
19. alpha(1)-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1.
Sulikowski T; Bauer BA; Patston PA
Protein Sci; 2002 Sep; 11(9):2230-6. PubMed ID: 12192078
[TBL] [Abstract][Full Text] [Related]
20. Bradykinin formation. Plasma and tissue pathways and cellular interactions.
Kaplan AP; Joseph K; Shibayama Y; Nakazawa Y; Ghebrehiwet B; Reddigari S; Silverberg M
Clin Rev Allergy Immunol; 1998; 16(4):403-29. PubMed ID: 9926288
[No Abstract] [Full Text] [Related]
[Next] [New Search]
